Search Within

Emily Ann Carbone

Formats
  1. Meeting Abstract (18)
  2. Journal Article (9)
Groups
  1. Department of Medicine (27)
  2. Genitourinary Oncology Service (27)
  3. Solid Tumor Oncology Division (27)
  4. Hematology-Oncology Fellows (10)
  5. Epidemiology and Biostatistics (9)
  6. GSK Faculty (9)

More Groups

People
  1. Howard Scher (27)
  2. Ethan Barnett (23)
  3. Melanie Hullings (10)
  4. Michael Morris (8)
  5. Daniel Danila (7)
  6. Jimmy Zhao (7)

More People

Years
  1. 2023 (3)
  2. 2022 (4)
  3. 2021 (6)
  4. 2020 (6)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (14)
  2. Cancer Research (3)
  3. Annals of Oncology (2)
  4. Clinical Cancer Research (2)
  5. European Urology (2)
  6. European Journal of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (14)
  2. American Association for Cancer Research (5)
  3. Elsevier Science, Inc. (2)
  4. Oxford University Press (2)
  5. American Medical Association (1)
  6. Elsevier Inc. (1)

More Publishers

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC
    Meeting Abstract

    Scher, H. I.; Schonhoft, J.; Hullings, M.; Carbone, E.; Barnett, E.; Sutton, R.; Jendrisak, A.; Landers, M. A.; Wang, Y.; Dittamore, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Characterization of SLFN11 protein expression in circulating tumor cells (CTCs) of patients with metastatic castration resistant prostate cancer (mCRPC) prior to platinum based chemotherapy
    Meeting Abstract

    Fernandez, L.; Poirier, J.; Rodriguez, A.; Hulling, M.; Richardson, R.; Sutton, R.; Jiles, R.; Schonhoft, J.; Lee, J.; Ebrahim, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Journal Article

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Vargas, H. A.; Rathkopf, D.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; more...
    JAMA Oncology (2019)

    Fulltext@MSK | Save
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Meeting Abstract

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Carbone, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Hulling, M.; Carbone, E.; Dittamore, R.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save